US stock · Healthcare sector · Pharmaceutical Retailers
Company Logo

Walgreens Boots Alliance, Inc.

WBANASDAQ

33.82

USD
+0.88
(+2.67%)
Pre Market
-10.10P/E
7Forward P/E
-0.48P/E to S&P500
29.170BMarket CAP
- -Div Yield

Walgreens Boots Alliance, Inc.

NASDAQ:WBA

RECENT
PRICE

33.82

P/E
RATIO

-10.10

(PEG:- -)

P/E RATIO
RELATIVE
TO S&P

-0.48

DIV
YLD

5.12%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.72 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 03/23:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Fiscal year

53.84

2.04

0.57

0.31

59.59

2.18

0.82

0.38

63.97

2.03

2.21

0.45

68.68

2.13

2.78

0.55

78.88

2.97

2.66

0.71

81.89

2.43

3.29

0.90

76.34

2.59

3.27

1.10

80.15

2.03

2.92

1.26

99.16

4.05

4.23

1.33

108.35

3.85

6.02

1.44

110.12

3.80

5.50

1.61

132.73

5.07

6.96

1.75

148.53

4.32

4.22

1.78

158.67

0.52

4.67

1.99

153.23

2.94

4.83

1.87

153.52

5.02

2.50

1.92

153.01

(3.99)

1.62

1.92

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

1.79

11.12

2.25

12.99

1.95

14.52

1.03

14.67

1.33

16.22

1.77

20.85

1.28

20.56

1.16

21.46

1.20

29.58

1.22

27.59

1.26

25.59

1.38

26.24

1.85

25.51

1.56

23.47

1.59

27.08

2.01

33.97

2.19

30.94

CAPEX per share

Book Value per share

999

991

990

982

915

875

946

953

1,043

1,083

1,074

991

922

879

865

864

864

Comm.Shares outs.(m)

14.4

0.8

1.1%

10.2

0.5

1.7%

10.8

0.2

2.1%

11.0

0.5

2.4%

9.4

0.6

2.5%

10.3

0.7

3.6%

14.4

0.8

2.9%

25.6

1.4

2.4%

21.0

1.0

1.6%

21.2

1.0

1.8%

20.8

0.9

2.0%

13.9

0.6

2.5%

13.6

0.6

3.0%

82.5

2.2

4.6%

17.0

0.6

3.7%

8.3

0.4

4.6%

(10.1)

(0.5)

5.1%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/11/22 | Q1)

Total liabilities
$68,293 m.

Total assets
$92,875 m.

Long-term debt
$29,303 m.

Cash and equiv.
$2,349 m.

Goodwill $22,582 m.

Retained earnings $37,811 m.

Common stock 864 m. shares

Market Capitalisation
$28,834 m. (as of 29/3/23)

71,633

4.8%

72,217

5.5%

76,392

5.5%

103,444

4.5%

117,351

5.1%

118,214

4.7%

131,537

4.9%

136,866

3.7%

139,537

0.9%

132,509

1.8%

132,703

1.0%

132,184

(4.6)%

Revenue (m)

Operating margin

1,166

2,127

1,283

2,450

1,316

1,932

1,742

4,220

1,718

4,173

1,654

4,078

1,770

5,024

2,038

3,982

1,927

456

1,973

2,542

1,990

4,337

1,985

(3,436)

Depreciation (m)

Net profit (m)

37.0%

3.0%

37.1%

3.4%

42.9%

2.5%

19.9%

4.1%

19.4%

3.6%

15.7%

3.4%

16.7%

3.8%

13.0%

2.9%

48.5%

0.3%

33.4%

1.9%

0.7%

3.3%

324.6%

(2.6)%

Income tax rate

Net profit margin

2,038

4,073

18,236

2,991

4,477

19,454

3,347

3,736

20,457

3,100

13,315

30,861

8,870

18,705

29,880

1,206

12,684

27,466

(3,821)

12,431

26,007

(7,069)

11,098

23,512

(8,997)

12,203

20,637

(6,240)

29,828

23,419

(5,681)

32,132

29,366

(8,513)

29,303

24,582

Working capital (m)

Long-term debt (m)

Equity (m)

8.8%

10.4%

11.7%

9.6%

11.4%

12.6%

7.3%

9.7%

9.4%

9.1%

8.6%

13.7%

8.4%

8.0%

14.0%

10.0%

8.5%

14.8%

12.1%

9.8%

19.3%

11.1%

7.9%

16.9%

1.3%

1.7%

2.2%

4.7%

5.1%

10.9%

7.0%

5.3%

14.8%

4.9%

(1.5)%

(14.0)%

ROIC

Return on capital

Return on equity

Working Capital

2020

2021

2022

Cash assets

516

1,193

1,358

Receivables

7,132

5,663

5,017

Inventory

9,451

8,159

8,353

Other

974

799

1,060

Current assets

18,073

15,814

16,902

Acc. Payable

14,458

11,136

11,255

Debt due

5,965

3,565

3,345

Other

6,647

7,353

7,983

Current liab.

27,070

22,054

22,583

63.0%

68.7%

57.6%

53.6%

37.9%

68.3%

67.2%

59.1%

62.5%

41.6%

57.7%

117.7%

65.4%

101.0%

58.7%

149.1%

(283.1)%

81.2%

36.4%

41.4%

59.2%

76.6%

149.9%

- -

Plowback ratio

Div.&Repurch. to FCF

Walgreens Boots Alliance, Inc. (US) started trading on December 3, 2014 (cik: 0001618921), operates in the Healthcare sector (Pharmaceutical Retailers industry), has 325,000 full-time employees, and is led by Ms. Rosalind Gates Brewer. Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

0.28%

7.53%

Cash flow

-21.13%

2.13%

Earnings

104.70%

59.54%

Dividends

-1.01%

5.64%

Book value

4.26%

6.28%

Insider trading

Type

Shares

Date

Lederer John Anthony

Award

822

01/26/23

Jarrett Valerie B

Award

685

01/26/23

Murphy Dominic

Award

685

01/26/23

Ban Kevin M.

Exempt

10,303

11/18/22

Ban Kevin M.

Sale

10,303

11/18/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2021

36,307

32,779

34,030

34,262

137,378

2022

33,901

33,756

32,597

32,449

132,703

2023

33,382

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2021

(0.36)

1.19

1.38

0.73

2.94

2022

4.14

1.02

0.33

(1.03)

4.47

2023

(4.31)

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2021

0.47

0.47

0.47

0.47

1.87

2022

0.48

0.49

0.48

0.47

1.92

2023

0.48

- -

- -

- -

- -

02/19/2023

Walgreens CEO Bets on Doctors Over Drugstores in Search for Growth

The Wall Street Journal - Read more...

02/13/2023

Opioid Settlement Money Is Coming. Two Ohio Counties Differ on How to Spend It.

The Wall Street Journal - Read more...

01/05/2023

Walgreens Sales Fall as Demand for Covid Vaccines Wanes

The Wall Street Journal - Read more...

01/05/2023

Walgreens Becomes First U.S. Pharmacy Chain to Say It Will Sell Abortion Pill

The Wall Street Journal - Read more...

11/07/2022

Walgreens Unit Strikes Roughly $9 Billion Deal With Summit Health

The Wall Street Journal - Read more...

11/02/2022

CVS, Walgreens to Pay More Than $10 Billion to Settle Opioid Lawsuits

The Wall Street Journal - Read more...

09/20/2022

Walgreens to Take Full Ownership of Shields Health

The Wall Street Journal - Read more...

08/17/2022

CVS, Walgreens and Walmart Ordered to Pay $650 Million to Ohio Counties in Opioid Case

The Wall Street Journal - Read more...

08/11/2022

Walgreens Offers Bonuses Up to $75,000 to Recruit Pharmacists

The Wall Street Journal - Read more...

08/10/2022

Walgreens Helped Fuel San Francisco Opioid Epidemic, Judge Rules

The Wall Street Journal - Read more...

07/08/2022

Higher Financing Costs, Lower Valuations Crimp M&A

The Wall Street Journal - Read more...

06/30/2022

Walgreens Profit Shrinks After Opioid Deal, Fewer Vaccinations

The Wall Street Journal - Read more...

05/04/2022

Walgreens Names Heads of Marketing, Merchandising and Product

The Wall Street Journal - Read more...

04/27/2022

Walmart, CVS Block or Delay Telehealth Adderall Prescriptions

The Wall Street Journal - Read more...

03/31/2022

Walgreens Posts Higher Sales, Powered by Covid-19 Vaccine, Testing Demand

The Wall Street Journal - Read more...

01/14/2022

Walgreens, CVS Shut Some Pharmacies on Weekends as Omicron Strains Staffing

The Wall Street Journal - Read more...

01/06/2022

Walgreens Posts Higher Sales and Profit From Covid-19 Demand

The Wall Street Journal - Read more...

01/06/2022

Bitcoin, Bed Bath & Beyond, Walgreens, Exxon: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/24/2021

Walgreens, Walmart, CVS Contributed to Opioid Epidemic, Ohio Jury Finds

The Wall Street Journal - Read more...

10/14/2021

Walgreens to Invest $5.2 Billion in VillageMD

The Wall Street Journal - Read more...

10/14/2021

Morgan Stanley, Citigroup, Plug Power: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/14/2021

Retailers Vetted Theranos Without Testing Devices

The Wall Street Journal - Read more...

09/24/2021

Pharmacies Prepare for Broader Covid-19 Booster Distribution

The Wall Street Journal - Read more...

09/15/2021

Biden Meets With Executives on Vaccine Mandate

The Wall Street Journal - Read more...

07/01/2021

Walgreens Sales Rise as Vaccinations Improve Prescriptions Business

The Wall Street Journal - Read more...

07/01/2021

Krispy Kreme, Micron Technology, CureVac: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

03/31/2021

Walgreens Reports Stronger Profit as Covid-19 Vaccine Rollout Ramps Up

The Wall Street Journal - Read more...

03/31/2021

Chewy, Deliveroo and Credit Suisse: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...